Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
EH12.2H7_BV421_1_040311
Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_1_040311
    Human peripheral blood lymphocytes were stained with CD3 FITC and CD279 (clone EH12.2H7) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).
  • EH12.2H7_BV421_2_040311
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
329919 25 tests £140
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329920 100 tests £275
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Geetha H. Mylvaganam, Daniel Rios 2017. Proc Natl Acad Sci U S A. 114(8):1976-1981. PubMed
  2. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  3. Gibellini L, et al. 2020. EMBO Mol Med. 12:e13001. PubMed
  4. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
  5. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
  6. Whitney JB, et al. 2018. Nat Commun. 9:5429. PubMed
  7. Komech EA, et al. 2022. Front Immunol. 13:973243. PubMed
  8. Wu VH, et al. 2020. JCI Insight. 5:00. PubMed
  9. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
  10. Mastelic-Gavillet B, et al. 2019. J Immunother Cancer. 7:257. PubMed
  11. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  12. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
  13. Goncharov MM, et al. 2022. Elife. 11:. PubMed
  14. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  15. Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
  16. Gupta R, et al. 2022. Front Immunol. 13:886442. PubMed
  17. Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
  18. Eberhardt K, et al. 2015. Clin Infect Dis. 61: 1615 - 1623. PubMed
  19. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
  20. Lindesmith LC, et al. 2020. Cell Mol Gastroenterol Hepatol. 0.586805556. PubMed
  21. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  22. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
  23. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  24. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  25. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  26. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
  27. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
  28. Harper J, et al. 2022. J Clin Invest. . PubMed
  29. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
  30. Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed
  31. Kreutmair S, et al. 2021. Immunity. . PubMed
  32. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
  33. Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed
  34. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
  35. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  36. Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
  37. André P et al. 2018. Cell. 175(7):1731-1743 . PubMed
  38. Sayin I, et al. 2018. J Exp Med. 7:40286. PubMed
  39. Xu L, et al. 2021. Front Oncol. 11:686156. PubMed
  40. Naidoo KK, et al. 2020. PLoS One. 15:e0242448. PubMed
  41. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  42. Seo IH, et al. 2021. Immune Netw. 21:e17. PubMed
  43. Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed
  44. Buggert M, et al. 2014. J Immunol. 192:2099. PubMed
  45. Buggert M, et al. 2014. J Immunol. 192:4685. PubMed
  46. Cao J, et al. 2018. Nat Commun. 9:77. PubMed
  47. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
  48. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
  49. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  50. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
  51. Pacheco Y, et al. 2013. J Immunol. 191:2072. PubMed
  52. Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed
  53. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
  54. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
  55. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  56. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
  57. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
  58. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  59. Routhu NK, et al. 2021. Immunity. 54(3):542-556.e9. PubMed
  60. Pilkinton MA, et al. 2017. Vaccine. 35:329. PubMed
  61. Lee J, et al. 2015. Clin Immunol. 159: 37-46. PubMed
  62. RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed
  63. Bradley T, et al. 2020. Nat Commun. 11:948. PubMed
  64. Horn C, et al. 2021. HIV Med. 22:397. PubMed
  65. Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed
  66. Gannon PO, et al. 2020. Cytotherapy. 22(12):780-791. PubMed
  67. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
  68. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  69. Han Q, et al. 2020. Cell Rep. 30:1553. PubMed
  70. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  71. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
  72. Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed
  73. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  74. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  75. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
  76. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
  77. Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
  78. Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed
  79. Claiborne D, et al. 2015. Proc Natl Acad Sci U S A. 112:1480. PubMed
  80. Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed
  81. Suzuki S, et al. 2020. Cancer Sci. 1943:111. PubMed
  82. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
  83. Paris R, et al. 2015. PLoS One. 10: 0144767. PubMed
  84. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
  85. Guéguen P, et al. 2021. Sci Immunol. 6:. PubMed
RRID
AB_10900818 (BioLegend Cat. No. 329919)
AB_10960742 (BioLegend Cat. No. 329920)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC, SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC, CyTOF®
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC-F
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC, Block, IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
Go To Top Version: 2    Revision Date: 01/22/2015

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Brilliant Violet 421™ anti-human CD279 (PD-1)

  • Purified anti-human CD279 (PD-1)

  • FITC anti-human CD279 (PD-1)

  • PE anti-human CD279 (PD-1)

  • APC anti-human CD279 (PD-1)

  • Alexa Fluor® 647 anti-human CD279 (PD-1)

  • PerCP/Cyanine5.5 anti-human CD279 (PD-1)

  • APC/Cyanine7 anti-human CD279 (PD-1)

  • Pacific Blue™ anti-human CD279 (PD-1)

  • PE/Cyanine7 anti-human CD279 (PD-1)

  • Purified anti-human CD279 (PD-1) (Maxpar® Ready)

  • Brilliant Violet 605™ anti-human CD279 (PD-1)

  • Ultra-LEAF™ Purified anti-human CD279 (PD-1)

  • Brilliant Violet 711™ anti-human CD279 (PD-1)

  • Brilliant Violet 785™ anti-human CD279 (PD-1)

  • Brilliant Violet 510™ anti-human CD279 (PD-1)

  • Biotin anti-human CD279 (PD-1)

  • PE/Dazzle™ 594 anti-human CD279 (PD-1)

  • Alexa Fluor® 488 anti-human CD279 (PD-1)

  • PerCP anti-human CD279 (PD-1)

  • GoInVivo™ Purified anti-human CD279 (PD-1)

  • Brilliant Violet 650™ anti-human CD279 (PD-1)

  • Alexa Fluor® 700 anti-human CD279 (PD-1)

  • APC/Fire™ 750 anti-human CD279 (PD-1)

  • TotalSeq™-A0088 anti-human CD279 (PD-1)

  • TotalSeq™-B0088 anti-human CD279 (PD-1)

  • TotalSeq™-C0088 anti-human CD279 (PD-1)

  • Brilliant Violet 750™ anti-human CD279 (PD-1)

  • TotalSeq™-D0088 anti-human CD279 (PD-1)

  • PE/Fire™ 640 anti-human CD279 (PD-1)

  • PE/Cyanine5 anti-human CD279 (PD-1)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account